The favorable characteristics of bispecific antibodies such as high specificity, high cytotoxic potential, and low immunogenicity, led us to design a bispecific antibody targeted to Vγ9 instead of CD3 and to HER2 expressed on several PDAC as well as on breast and prostate cancer, which could be easily replaced by another tumor target antigen of interest. The gene discussed is ERBB2; the disease is prostate carcinoma.